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Background
The effect of raloxifene, a selective estrogen-receptor modulator, on coronary 
heart disease (CHD) and breast cancer is not established.
Methods
We randomly assigned 10,101 postmenopausal women (mean age, 67.5 years) with 
CHD or multiple risk factors for CHD to 60 mg of raloxifene daily or placebo and 
followed them for a median of 5.6 years. The two primary outcomes were coro-
nary events (i.e., death from coronary causes, myocardial infarction, or hospitaliza-
tion for an acute coronary syndrome) and invasive breast cancer.
Results
As compared with placebo, raloxifene had no significant effect on the risk of pri-
mary coronary events (533 vs. 553 events; hazard ratio, 0.95; 95 percent confidence 
interval, 0.84 to 1.07), and it reduced the risk of invasive breast cancer (40 vs. 70 
events; hazard ratio, 0.56; 95 percent confidence interval, 0.38 to 0.83; absolute risk 
reduction, 1.2 invasive breast cancers per 1000 women treated for one year); the 
benefit was primarily due to a reduced risk of estrogen-receptor–positive invasive 
breast cancers. There was no significant difference in the rates of death from any 
cause or total stroke according to group assignment, but raloxifene was associated 
with an increased risk of fatal stroke (59 vs. 39 events; hazard ratio, 1.49; 95 percent 
confidence interval, 1.00 to 2.24; absolute risk increase, 0.7 per 1000 woman-years) 
and venous thromboembolism (103 vs. 71 events; hazard ratio, 1.44; 95 percent 
confidence interval, 1.06 to 1.95; absolute risk increase, 1.2 per 1000 woman-years). 
Raloxifene reduced the risk of clinical vertebral fractures (64 vs. 97 events; hazard 
ratio, 0.65; 95 percent confidence interval, 0.47 to 0.89; absolute risk reduction, 1.3 
per 1000).
Conclusions
Raloxifene did not significantly affect the risk of CHD. The benefits of raloxifene 
in reducing the risks of invasive breast cancer and vertebral fracture should be 
weighed against the increased risks of venous thromboembolism and fatal stroke. 
(ClinicalTrials.gov number, NCT00190593.)
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Raloxifene is a nonsteroidal selec-tive estrogen-receptor modulator (SERM) that binds to the estrogen receptor, lead-
ing to estrogen-agonist effects in some tissues 
and estrogen-antagonist effects in others.1 Raloxi-
fene therapy has been associated with improve-
ment in the levels of serum lipoprotein choles-
terol,2,3 fibrinogen,3 and homocysteine.4 The 
fav orable effect of raloxifene on markers of car-
diovascular risk, coupled with evidence from 
observational studies that treatment with estro-
gen was associated with a reduced risk of coro-
nary heart disease (CHD) in postmenopausal 
women,5,6 led to the design of the Raloxifene 
Use for The Heart (RUTH) trial to determine the 
effect of raloxifene on clinical coronary events. 
After the RUTH trial began in 1998, results of the 
Heart and Estrogen/Progestin Replacement Study 
(HERS)7 and the Women’s Health Initiative 
(WHI) clinical trials8,9 showed no reduction in 
the risk of CHD after treatment with estrogen or 
estrogen plus progestin. A secondary analysis of 
data from the Multiple Outcomes of Raloxifene 
Evaluation (MORE) trial (an osteoporosis-treat-
ment trial) showed no significant overall effect 
of raloxifene on cardiovascular events but sug-
gested a reduced risk among women who were at 
increased risk for cardiovascular events.10
Raloxifene has antiestrogenic effects in the 
breast, competitively blocking estrogen-induced 
DNA transcription11 and inhibiting the growth 
of estrogen-stimulated mammary cancers in ani-
mals.12 After the RUTH trial began, a secondary 
analysis of data from the MORE trial showed that 
raloxifene reduced the risk of invasive breast can-
cer by 72 percent.13
We conducted the RUTH trial to assess the 
risks and benefits of treatment with raloxifene 
in women with or at increased risk for CHD, 
with the primary aims of determining effects on 
coronary outcomes and invasive breast cancer.
Methods
RUTH was an international, multicenter, ran-
domized, double-blind, placebo-controlled trial. 
A detailed description of the design and study 
population has been published elsewhere.14,15 
The two primary objectives were to determine the 
effect of raloxifene as compared with placebo 
on the incidence of coronary events (i.e., death 
from coronary causes, nonfatal [including silent] 
myocardial infarction, or hospitalization for an 
acute coronary syndrome other than myocardial 
infarction) and invasive breast cancer.
The executive committee developed the proto-
col in collaboration with the sponsor. An inde-
pendent data and safety monitoring board with 
independent statistical support performed inter-
im analyses of safety and efficacy. The data were 
analyzed by the sponsor according to the pre-
specified analysis plan. The executive committee 
had unrestricted request-based access to data, 
which were retained by the sponsor. All authors 
were involved in interpreting the data and draft-
ing the manuscript and vouch for the accuracy 
and completeness of the reported data. Data re-
ported are those available as of February 2, 2006.
The protocol was approved by the ethics re-
view board at each investigative site. All women 
gave written informed consent for participation 
in accordance with the principles of the Decla-
ration of Helsinki.
Study Population
Between June 1998 and August 2000, 10,101 post-
menopausal women were randomly assigned to 
treatment or placebo at 177 sites in 26 countries. 
Eligible women were 55 years of age or older, were 
one year or more postmenopausal, and had es-
tablished CHD or were at increased risk for CHD.14 
Participants were required to have a cardiovas-
cular risk score of 4 or more, according to a point 
system that takes into account the presence of the 
following14: established CHD (4 points), arterial 
disease of the leg (4 points), an age of at least 70 
years (2 points), diabetes mellitus (3 points), ciga-
rette smoking (1 point), hypertension (1 point), 
and hyperlipidemia (1 point).
Exclusion criteria were a myocardial infarction, 
coronary-artery bypass grafting, or percutaneous 
coronary intervention within three months be-
fore randomization; a history of cancer or venous 
thromboembolism; a life expectancy of less than 
five years; unexplained uterine bleeding within six 
months before randomization; New York Heart 
Association class III or IV heart failure; chronic 
liver or renal disease; use of oral or transdermal 
estrogens within six months before randomization; 
or current use of other sex hormones or SERMs.
Treatment and Study Procedures
Eligible women were randomly assigned to 60 mg 
of raloxifene a day orally (Evista, Eli Lilly) or to 
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identical-appearing placebo (Fig. 1). Randomiza-
tion was performed with the use of an interactive 
voice-response telephone system stratified accord-
ing to study site. At each biannual visit or tele-
phone contact, adverse events, outcomes, and ad-
herence to study medication were ascertained. 
Electrocardiography (ECG) was performed at base-
line, year 2, year 4, and the final visit. Mammog-
raphy and clinical breast examinations were per-
formed at randomization and every two years 
thereafter. Serum lipid levels were measured after 
an overnight fast at baseline, year 1, year 5, and 
the final visit.
Investigators, participants, laboratory staff, and 
the sponsor (Eli Lilly) were blinded to partici-
pants’ treatment assignment. Treatment assign-
ment was revealed to investigators only for rea-
sons of participants’ safety. The study drug was 
permanently discontinued when the treatment 
assignment was revealed to a participant (26 
women) or breast cancer or venous thromboem-
bolism was diagnosed. The study drug was tem-
porarily discontinued during periods of prolonged 
immobilization or if the participant took estro-
gen-containing preparations, other hormonal 
agents, or SERMs.
Outcomes
Reported outcomes of coronary events, breast 
cancer, stroke, venous thromboembolism, and 
death were adjudicated by committees of experts 
who were unaware of participants’ treatment as-
signment and who were not employees of the 
sponsor. Employees of the sponsor, who were un-
aware of the treatment assignment, adjudicated 
the secondary outcomes of fracture, myocardial 
revascularization, noncoronary arterial revascu-
larization, amputation of a leg, and hospitalization 
for any cause.
Coronary Events
The primary coronary outcome was defined as 
the first of any of the following events: death 
from coronary causes (i.e., acute myocardial in-
farction, sudden or unwitnessed death, heart fail-
ure, or death related to a coronary-artery proce-
dure), myocardial infarction, or hospitalization 
for an acute coronary syndrome other than myo-
10,101 Women underwent
randomization
11,767 Women signed informed
consent
1666 Excluded from participation
1411 Did not meet inclusion criteria
255 Met exclusion criteria
554 Died
430 Discontinued the study
595 Died
483 Discontinued the study
5057 Assigned to placebo
3979 Completed the study
5044 Assigned to raloxifene,
60 mg/day
4060 Completed the study
Figure 1. Enrollment, Treatment Assignment, and Follow-up in the Trial.
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cardial infarction.14 Myocardial infarction was 
diagnosed if at least one of the following was 
present: ischemic symptoms and abnormal levels 
of cardiac enzymes, with or without new, equivo-
cal changes on ECG; a new pathological Q wave, 
with or without ischemic symptoms or abnormal 
levels of cardiac enzymes; and new pathological 
Q waves or markedly abnormal levels of cardiac 
enzymes after invasive coronary procedures. Hos-
pitalization for an acute coronary syndrome was 
defined as hospitalization for or the development 
during hospitalization of cardiac symptoms with 
new changes in the ST-T segment on ECG or ab-
normal levels of cardiac enzymes or troponin.
Breast Cancer
Breast cancers were confirmed by pathology re-
ports. They were classified as invasive or nonin-
vasive and according to estrogen-receptor status.
Secondary Outcomes
Secondary mortality outcomes were death from 
coronary causes, death from cardiovascular causes 
(death from coronary causes and death from non-
coronary cardiovascular causes such as cerebro-
vascular, venous thromboembolic, atherosclerotic 
noncoronary vascular disease, and other cardio-
vascular causes), and death from any cause (death 
from cardiovascular causes and death from non-
cardiovascular causes such as cancer, accident, sui-
cide, homicide, or any other cause). The cause of 
death was assigned on the basis of available clin-
ical information, the death certificate, or autop-
sy. Stroke was defined as the rapid onset of a per-
sistent neurologic deficit lasting more than 24 
hours, in most cases supported by findings on im-
aging studies. A venous thromboembolic event 
required clinical symptoms supported by relevant 
diagnostic studies. Revascularization included 
myocardial and noncoronary arterial revascular-
izations. Nontraumatic amputations of the leg in-
cluded those above and those below the knee. All 
reported clinical fractures were validated by re-
view of radiology reports. Hospitalization for any 
cause was defined as hospitalization for at least 
24 hours.
Adverse Events
Adverse events were recorded by the investigator 
at each visit on the basis of unsolicited reporting by 
the participant. All adverse events were classified 
according to the Medical Dictionary for Regula-
tory Activities (MedDRA, a registered trademark 
of the International Federation of Pharmaceutical 
Manufacturers and Associations), developed un-
der the auspices of the International Conference 
on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use. 
Common adverse events were defined as events 
at the MedDRA Preferred Term level occurring in 
at least 2 percent of women assigned to raloxifene. 
Special search categories were established with 
the use of MedDRA terms to comprehensively de-
scribe adverse events of potential relevance to 
SERMs or hormone therapy.
Serious adverse events were defined as events 
that were life-threatening, severe, or permanently 
disabling; cancer; or clinically significant for any 
other reason. These were identified as primary 
or secondary outcomes or, in the case of cancer, 
through a special search category established with 
the use of MedDRA terms.
Statistical AnalysIs
Comparisons of baseline characteristics between 
treatment groups were performed with the use of 
one-way analysis of variance for continuous vari-
ables and chi-square tests for categorical variables. 
Primary analyses used time-to-event methods on 
the basis of the intention-to-treat principle. Data 
on women who did not have an event were cen-
sored on the date when study information was last 
collected or on the date of death. Relative incidenc-
es of the primary outcomes of coronary events and 
invasive breast cancer were compared with the use 
of a log-rank test. Unadjusted Cox proportional-
hazards models were used to estimate hazard 
ratios with 95 percent confidence intervals for 
the primary and secondary outcomes.
Adverse events were analyzed with a Cochran–
Mantel–Haenszel test stratified according to 
country. If fewer than five events occurred, no 
statistical test was performed. Baseline labora-
tory values and percentage change from baseline 
to one year were analyzed with the use of an un-
adjusted ranked one-way analysis of variance.
Secondary analyses were performed for the 
primary outcomes in an “as-treated” population, 
defined as women who were at least 70 percent 
adherent to the study treatment on the basis of 
the pill count. The primary outcome of coronary 
events was assessed separately for those with CHD 
and for those at increased risk for CHD with the 
use of Cox proportional-hazards models.
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All analyses were prespecified, except the in-
teraction test of the primary outcome of coro-
nary events in women with established CHD as 
compared with those at increased risk for CHD. 
Reported P values are two-sided. Statistical analy-
ses were performed with the use of SAS software, 
version 8.2 (SAS Institute).
The power calculations were based on as-
sumptions of a 20.0 percent relative reduction 
in the risk of coronary events and a 58.5 percent 
relative reduction in the risk of invasive breast 
cancer with raloxifene, given a statistical power of 
80 percent and a two-sided alpha level of 0.0423 
for coronary events and 0.008 for invasive breast 
cancer. Other outcomes were tested at a signifi-
cance level of 0.05, except interaction effects, 
which were tested at a significance level of 0.10. 
No adjustments were made for multiple com-
parisons.
Results
For both treatment groups, the median duration 
of follow-up was 5.56 years (range, 0.01 to 7.06) 
and the median exposure to the study drug was 
5.05 years. The study was completed by 79 percent 
of women in the placebo group and 80 percent in 
the raloxifene group (P = 0.02). Overall, 71 percent 
of women in the placebo group and 70 percent in 
the raloxifene group took at least 70 percent of the 
assigned medication and were classified as adher-
ent to treatment (P = 0.62).
The treatment groups were similar with respect 
to baseline characteristics (Table 1), except the 
raloxifene group had a slightly higher cardiovas-
cular risk score and a higher proportion of women 
reporting coronary-artery bypass grafting. Dur-
ing the trial, both the placebo and raloxifene 
groups had increases in the use of statins (21 
percent and 19 percent, respectively), antihyper-
tensive agents (6 percent and 7 percent), and as-
pirin (13 percent and 15 percent) (P>0.05 for each 
comparison).
Primary Outcomes
There was no significant difference between the 
raloxifene group and the placebo group in the in-
cidence of the primary outcome of death from 
coronary causes, nonfatal myocardial infarction, 
or hospitalization for an acute coronary syndrome 
(hazard ratio, 0.95; 95 percent confidence interval, 
0.84 to 1.07) (Table 2 and Fig. 2A), or for death 
from coronary causes, nonfatal myocardial in-
farction, or hospitalization for an acute coronary 
syndrome individually. The effect of treatment on 
the primary outcome of coronary events did not 
differ significantly among women with estab-
lished CHD (hazard ratio, 0.97; 95 percent confi-
dence interval, 0.83 to 1.12) or women at in-
creased risk for CHD (hazard ratio, 0.91; 95 
percent confidence interval, 0.74 to 1.11) (P val-
ue for the interaction = 0.64). There were 18 other 
prespecified subgroup analyses for the primary 
coronary outcome (including age and the pres-
ence or absence of risk factors for CHD); there 
were no significant treatment-group interactions 
for any subgroup (P>0.10). The results of as-
treated analyses were similar to those of the in-
tention-to-treat analyses for the primary coro-
nary outcome (hazard ratio for the comparison 
of the raloxifene group with the placebo group, 
0.96; 95 percent confidence interval, 0.83 to 1.12; 
P = 0.61) and its individual components (P>0.05 
for each comparison).
Raloxifene reduced the incidence of the pri-
mary outcome of invasive breast cancer (hazard 
ratio, 0.56; 95 percent confidence interval, 0.38 to 
0.83) (Table 2 and Fig. 2B), primarily because of 
a reduction in estrogen-receptor–positive invasive 
breast cancer (Table 2). The absolute risk reduc-
tion per 1000 women treated with raloxifene for 
one year was 1.2 cases of invasive breast cancer 
and 1.2 cases of estrogen-receptor–positive inva-
sive breast cancer. The results of the as-treated 
analysis for invasive breast cancer were similar 
(hazard ratio for the comparison of the raloxifene 
group with the placebo group, 0.61; 95 percent 
confidence interval, 0.39 to 0.95; P = 0.03). There 
was no significant difference between treatment 
groups in the incidence of estrogen-receptor–neg-
ative invasive breast cancer (Table 2).
The effect of treatment on invasive breast can-
cer did not differ significantly among women 
with a five-year estimated risk of invasive breast 
cancer of less than 1.66 percent on the basis of 
the Gail score16 (hazard ratio, 0.49; 95 percent 
confidence interval, 0.28 to 0.88) or 1.66 percent 
or more (hazard ratio, 0.65; 95 percent confi-
dence interval, 0.38 to 1.09; P value for the inter-
action = 0.50). There were eight other prespeci-
fied subgroup analyses for invasive breast cancer; 
there were no significant treatment-group inter-
actions for any subgroup (P>0.1) except the ovari-
ectomy subgroup analysis (P = 0.07).
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Secondary Outcomes
The overall incidence of stroke did not differ sig-
nificantly between treatment groups, but the in-
cidence of fatal stroke was 49 percent higher in 
the raloxifene group than in the placebo group 
(absolute risk increase, 0.7 per 1000 woman-years). 
The incidence of venous thromboembolic events 
was 44 percent higher in the raloxifene group 
than in the placebo group (absolute risk increase, 
1.2 per 1000 woman-years). There was a 33 percent 
lower incidence of all breast cancers (absolute 
risk reduction, 0.9 per 1000 woman-years) and 
a 35 percent lower incidence of clinical vertebral 
fractures (absolute risk reduction, 1.3 per 1000 
woman-years) in the raloxifene group (Table 2).
There was no significant difference between 
treatment groups in the rates of death from any 
cause or overall death from cardiovascular causes. 
The incidence of death from noncardiovascular 
causes was lower in the raloxifene group than in 
Table 1. Baseline Characteristics of 10,101 Women.*
Characteristic
Raloxifene
(N = 5044)
Placebo
(N = 5057) P Value
Age (yr) 67.5±6.6 67.5±6.7 0.86
Age ≥70 yr (%) 38.7 39.2 0.63
White race (%)† 84.0 84.0 0.96
Region (%) 1.00
Western Europe 46.3 46.3
Eastern Europe 22.9 22.9
Latin or South America 13.6 13.5
North America 10.2 10.2
Asia Pacific 4.9 5.0
Africa 2.1 2.2
Body-mass index‡ 28.8±5.2 28.7±5.1 0.27
Waist circumference (cm) 93.9±13.2 93.9±13.1 0.86
Current smoker (%)§ 12.0 12.8 0.22
Alcohol consumption (%) 42.7 43.1 0.68
Vigorous physical activity ≥3 times per week (%) 18.8 18.3 0.57
Previous use of therapy (%)
Estrogen 14.0 14.0 0.93
Estrogen plus progestin 5.7 6.5 0.10
Hysterectomy (%) 22.7 23.3 0.48
Postmenopausal years 19.3±8.8 19.5±8.8 0.32
Presence of diabetes mellitus (%)¶ 45.7 45.8 0.89
Systolic blood pressure (mm Hg) 145.8±20.3 145.4±20.1 0.37
Diastolic blood pressure (mm Hg) 82.0±10.5 82.0±10.4 0.98
Hypertension (%)∥ 77.9 77.8 0.94
Hyperlipidemia (%)** 73.3 73.6 0.75
History of coronary artery disease (%)†† 50.3 49.4 0.34
Arterial disease affecting the legs (%) 10.8 10.7 0.89
Cardiovascular risk score‡‡ 7.9±4.0 7.8±3.7 0.03
Cardiovascular risk score category (%)‡‡ 0.68
4–6 50.1 50.6
>6 49.5 49.1
Five-year predicted risk of invasive breast cancer (%)§§ 1.73±0.76 1.73±0.77 0.85
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the placebo group (absolute risk reduction, 1.7 per 
1000 woman-years); no specific disease category 
explained this finding. Fewer women in the ral-
oxifene group than in the placebo group had one 
or more hospitalizations for any cause (52 percent 
vs. 54 percent; hazard ratio, 0.91; 95 percent con-
fidence interval, 0.87 to 0.96; P = 0.001).
Adverse Events
There was no significant difference between the 
treatment groups in the number of women with 
one or more reported adverse events (93 percent 
in both groups, P = 0.71). More women in the ral-
oxifene group than in the placebo group perma-
nently discontinued use of the study drug because 
of an adverse event (22 percent vs. 20 percent, 
P = 0.01).
Four common adverse events (an acute coro-
nary syndrome, anxiety, constipation, and osteo-
porosis) were reported more frequently in the 
placebo group than in the raloxifene group, and 
seven (arthritis, cholelithiasis, dyspepsia, hot flush, 
intermittent claudication, muscle spasm, and pe-
ripheral edema) were reported more frequently in 
the raloxifene group than in the placebo group 
(P≤0.05). Hot flushes, leg cramps, peripheral ede-
ma, and gallbladder disease, all special search 
categories, were more common in women assigned 
Table 1. (Continued.)
Characteristic
Raloxifene
(N = 5044)
Placebo
(N = 5057) P Value
Five-year predicted risk of invasive breast cancer ≥1.66 
percent (%)§§
41.7 41.2 0.61
Family history of breast cancer (%) 9.8 9.7 0.85
Medication use at baseline (%)
Statin 47.2 46.7 0.59
Antihypertensive agent 89.6 89.4 0.83
Aspirin 56.4 56.7 0.82
Oral hypoglycemic agent 34.0 33.8 0.84
Insulin 13.8 14.4 0.39
Fasting serum glucose level (mg/dl)
Women with diabetes mellitus 180.7±71.7 181.1±71.1 0.66
Women without diabetes mellitus 102.1±16.0 102.1±16.1 0.67
LDL cholesterol level (mg/dl) 121.7±37.1 122.1±37.4 0.67
HDL cholesterol level (mg/dl) 52.3±14.2 52.6±14.4 0.61
* Plus–minus values are means ±SD. Because of rounding, percentages may not total 100. To convert values for glu-
cose to millimoles per liter, multiply by 0.05551. To convert values for cholesterol to millimoles per liter, multiply by 
0.0259. LDL denotes low-density lipoprotein, and HDL high-density lipoprotein.
† Race or ethnic group was self-designated.
‡ Body-mass index is the weight in kilograms divided by the square of the height in meters.
§ Smoking was defined as self-reported smoking of an average of at least 10 cigarettes a day during the six months be-
fore visit 1.
¶ Diabetes was defined as self-reported diabetes mellitus and the use of oral hypoglycemic medication or insulin, or as 
a fasting serum glucose level of more than 140 mg per deciliter at visit 1.
∥ Hypertension was defined as self-reported hypertension and the use of antihypertensive agents, or systolic blood 
pressure greater than 160 mm Hg or diastolic blood pressure greater than 95 mm Hg on at least two measurements.
** Hyperlipidemia was defined as the use of lipid-lowering medications or a fasting LDL cholesterol level of more than 
160 mg per deciliter, or a fasting HDL cholesterol level of less than 45 mg per deciliter, with a fasting triglyceride level 
of more than 250 mg per deciliter.
†† A history of coronary artery disease includes previous myocardial infarction, coronary-artery bypass grafting, percuta-
neous coronary intervention, or angina with documented coronary heart disease.
‡‡ The cardiovascular risk score was calculated on the basis of the presence of the following risk factors for a major cor-
onary event14: established coronary heart disease (4 points), arterial disease involving the legs (4 points), an age of at 
least 70 years (2 points), diabetes mellitus (3 points), cigarette smoking (1 point), hypertension (1 point), and hyper-
lipidemia (1 point).
§§ The five-year predicted risk was calculated on the basis of the presence or absence of recognized risk factors for 
breast cancer, with the use of the Gail model.16
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Table 2. Incidence of and Hazard Ratios for Primary (Combined Coronary End Point and Invasive Breast Cancer) and Secondary End Points.*
End Point
Raloxifene
(N = 5044)
Placebo
(N = 5057) 
Hazard Ratio
(95% CI) P Value
no. of events (annualized rate [%])
Cardiovascular
Combined coronary end point 533 (2.06) 553 (2.16) 0.95 (0.84–1.07) 0.40
Death from coronary causes 253 (0.95) 273 (1.03) 0.92 (0.77–1.09) 0.31
Nonfatal myocardial infarction† 183 (0.69) 208 (0.80) 0.87 (0.71–1.06) 0.16
Hospitalization for an acute coronary syndrome other than myocardial 
infarction
169 (0.64) 185 (0.71) 0.90 (0.73–1.11) 0.34
Death from cardiovascular causes, nonfatal myocardial infarction, hospital-
ization for an acute coronary syndrome, or stroke
789 (3.09) 767 (3.05) 1.02 (0.92–1.12) 0.76
Death from cardiovascular causes, nonfatal myocardial infarction, hospital-
ization for an acute coronary syndrome, myocardial revasculariza-
tion, or stroke
1067 (4.33) 1041 (4.28) 1.01 (0.93–1.10) 0.80
Stroke 249 (0.95) 224 (0.86) 1.10 (0.92–1.32) 0.30
Hemorrhagic 18 (0.07) 30 (0.11) 0.59 (0.33–1.06) 0.07
Ischemic 198 (0.75) 171 (0.65) 1.15 (0.93–1.41) 0.19
Undetermined 39 (0.15) 30 (0.11) 1.28 (0.80–2.07) 0.30
Venous thromboembolic event 103 (0.39) 71 (0.27) 1.44 (1.06–1.95) 0.02
Pulmonary embolism 36 (0.14) 24 (0.09) 1.49 (0.89–2.49) 0.13
Deep-vein thrombosis 65 (0.24) 47 (0.18) 1.37 (0.94–1.99) 0.10
All revascularizations 611 (2.44) 615 (2.49) 0.98 (0.88–1.10) 0.73
Nontraumatic amputation of the leg 41 (0.15) 44 (0.17) 0.92 (0.60–1.41) 0.70
Breast cancer
Invasive breast cancer 40 (0.15) 70 (0.27) 0.56 (0.38–0.83) 0.003
Estrogen-receptor–positive 25 (0.09) 55 (0.21) 0.45 (0.28–0.72) <0.001
Estrogen-receptor–negative 13 (0.05) 9 (0.03) 1.44 (0.61–3.36) 0.40
Unknown estrogen-receptor status 2 (0.007) 6 (0.02) 0.33 (0.07–1.63) 0.15
Noninvasive breast cancer‡ 11 (0.04) 5 (0.02) 2.17 (0.75–6.24) 0.14
All breast cancers§ 52 (0.20) 76 (0.29) 0.67 (0.47–0.96) 0.03
Fracture
Clinical nonvertebral 428 (1.67) 438 (1.73) 0.96 (0.84–1.10) 0.59
Clinical vertebral 64 (0.24) 97 (0.37) 0.65 (0.47–0.89) 0.007
Death
Any cause 554 (2.07) 595 (2.25) 0.92 (0.82–1.03) 0.16
Cardiovascular cause 362 (1.35) 355 (1.34) 1.01 (0.87–1.17) 0.91
Noncoronary 107 (0.40) 81 (0.31) 1.31 (0.98–1.74) 0.07
Cerebrovascular (stroke)¶ 59 (0.22) 39 (0.15) 1.49 (1.00–2.24) 0.05
Venous thromboembolism 10 (0.04) 5 (0.02) 1.98 (0.68–5.79) 0.20
Noncardiovascular cause 188 (0.70) 231 (0.87) 0.80 (0.66–0.98) 0.03
Cancers 97 (0.36) 103 (0.39) 0.93 (0.70–1.23) 0.61
Noncancer 91 (0.34) 128 (0.48) 0.70 (0.54–0.92) 0.01
Cause unavailable 4 (0.02) 9 (0.03) 0.44 (0.14–1.43) 0.16
* The primary coronary end point was death from coronary causes, nonfatal myocardial infarction, or hospitalization for an acute coronary 
syndrome, other than myocardial infarction, whichever occurred first. For any participant with multiple coronary events, each first event 
in each subcategory was counted separately. CI denotes confidence interval.
† This end point includes 9 women in the placebo group and 24 in the raloxifene group who had silent myocardial infarction.
‡ All noninvasive breast cancers were ductal carcinoma in situ.
§ This end point includes invasive and noninvasive breast cancers, plus one additional breast cancer in each treatment group for which the 
invasiveness could not be determined.
¶ For four deaths in the placebo group and four in the raloxifene group, the strokes reported by the investigator were not adjudicated as 
strokes by the stroke committee. For one death in the raloxifene group, the investigator did not report the stroke as an end point, and it 
was therefore not reviewed by the stroke committee. These nine strokes were not included in the analysis of the end point of stroke.
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to raloxifene than to placebo (Table 3). The rates 
of cholecystectomy did not differ significantly 
between the treatment groups (P = 0.25). The inci-
dences of endometrial cancer and all cancers other 
than breast cancer did not differ significantly 
between treatment groups.
Changes in Lipoprotein Levels
From baseline to year 1, there was a 3.6 percent 
increase in the level of low-density lipoprotein 
(LDL) cholesterol in the placebo group as com-
pared with a 4.4 percent decrease in the level in 
the raloxifene group (P<0.001), and a 0.9 percent 
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Figure 2. Cumulative Incidence of the Primary Outcomes of Coronary Events (Death from Coronary Causes, Nonfatal 
Myocardial Infarction, or Hospitalization for an Acute Coronary Syndrome Other Than Myocardial Infarction) (Panel A) 
and Invasive Breast Cancer (Panel B).
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increase in the level of high-density lipoprotein 
(HDL) cholesterol in the placebo group as com-
pared with a 2.3 percent increase in the level in 
the raloxifene group (P<0.001).
Discussion
Treatment with raloxifene for a median of 5.6 
years did not significantly affect the risk of cor-
onary events. Such treatment decreased the risks 
of invasive breast cancer and clinical vertebral frac-
ture and increased the risks of venous thrombo-
embolic events and fatal stroke.
When the RUTH trial was designed, compel-
ling evidence from many observational studies 
suggested that postmenopausal estrogen therapy 
was cardioprotective.5,6 However, three large tri-
als of postmenopausal treatment with hormones7-9 
subsequently failed to show a cardioprotective 
effect of estrogen, and the trials of estrogen plus 
progestin7,8 showed an early increased risk. We 
found that treatment with raloxifene did not sig-
nificantly affect the risk of coronary events among 
women with CHD or among women at high risk 
for CHD, nor did it cause an early increase in the 
risk of CHD. These results confirm the results of 
the MORE trial, in which raloxifene had a null 
effect on coronary disease in postmenopausal 
women with osteoporosis, but they do not provide 
support for the cardioprotective effect observed 
in a post hoc analysis of women in the MORE 
trial who were at high cardiovascular risk.10 The 
narrow 95 percent confidence interval for the ef-
fect of raloxifene on the primary coronary out-
come suggests that raloxifene is unlikely to reduce 
coronary risk more than 16 percent or to increase 
coronary risk more than 7 percent.
Raloxifene had moderate effects on LDL cho-
lesterol and HDL cholesterol levels that were of 
a lesser magnitude than the changes achieved by 
other medications shown to be cardioprotective.17 
The use of lipid-lowering medications, antihyper-
tensive agents, and antiplatelet agents was en-
couraged in the RUTH trial and increased during 
Table 3. Adverse Events.
Adverse Event
Raloxifene
(N = 5044)
Placebo
(N = 5057) P Value
number of participants (percent)
Hot flushes 401 (8.0) 244 (4.8) <0.001
Leg cramps 489 (9.7) 341 (6.7) <0.001
Peripheral edema 725 (14.4) 610 (12.1) <0.001
Gallbladder disease* 230 (5.6) 186 (4.5) 0.03
Influenza-like syndrome 21 (0.4) 31 (0.6) 0.17
Cataracts 374 (7.4) 391 (7.7) 0.56
Benign gynecologic conditions† 102 (2.0) 107 (2.1) 0.74
Atrial fibrillation 325 (6.4) 331 (6.5) 0.84
All cancers‡ 286 (5.7) 281 (5.6) 0.79
Endometrial cancer§ 21 (0.5) 17 (0.4) 0.53
Uterine sarcoma¶ 1 (<0.01) 0 —
Ovarian cancer∥ 17 (0.4) 10 (0.2) 0.17
* This category includes cholecystitis, cholelithiasis, and miscellaneous other gallbladder diseases. Participants who re-
ported having undergone a cholecystectomy at baseline (and who reported no subsequent gallbladder disease) were 
 excluded. For this analysis, there were 4111 participants in the placebo group and 4144 in the raloxifene group.
† This category includes benign cervical, uterine, vaginal, vulvar, and ovarian neoplasms, postmenopausal bleeding, uter-
ine polyps, cysts, fibroids, hyperplasia, and other conditions.
‡ This category excludes breast cancer. The most commonly reported were gastrointestinal cancers (1.2 percent in each 
treatment group), basal-cell carcinoma (1.1 percent in each treatment group), reproductive cancers (placebo group, 0.7 
percent; raloxifene group, 0.9 percent), and respiratory cancers (placebo group, 0.8 percent; raloxifene group, 0.7 percent).
§ Only women with an intact uterus were included — 3882 women in the placebo group and 3900 in the raloxifene group.
¶ The one case was reported by the investigator as low malignant leiosarcoma.
∥ Only women with at least one ovary were considered — 4606 women in the placebo group and 4559 in the raloxifene group.
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the trial. The use of cardioprotective medications 
did not differ significantly between the treatment 
groups and is unlikely to explain the null results. 
However, the lower-than-expected rate of coronary 
events may reflect the substantial use of these 
medications.
Women in the raloxifene group had a 55 per-
cent lower risk of estrogen-receptor–positive in-
vasive breast cancer than did women in the placebo 
group (absolute risk reduction, 1.2 estrogen-recep-
tor–positive invasive breast cancers per 1000 wom-
en treated for one year). This reduction is con-
sistent with that observed in postmenopausal 
women in the MORE trial.13 The relative reduc-
tion in the risk of invasive breast cancer was 
also similar to that seen among women at in-
creased risk for invasive breast cancer treated 
with tamoxifen in the Breast Cancer Prevention 
Trial.18 The effect of treatment with raloxifene in 
the RUTH trial was similar, regardless of the five-
year predicted risk of invasive breast cancer, on 
the basis of the Gail score.16
Although participants in the RUTH trial were 
not selected on the basis of an increased risk of 
breast cancer, 41 percent had a five-year predicted 
risk of 1.66 percent or greater16 (Table 1). This 
estimated risk would have made them eligible 
for the Breast Cancer Prevention Trial and the 
Study of Tamoxifen and Raloxifene (STAR).18,19 
The STAR results indicate that raloxifene is as 
effective as tamoxifen in reducing the risk of in-
vasive breast cancer among women at increased 
risk for invasive breast cancer but is associated 
with fewer uterine cancers and venous thrombo-
embolic events.19
Results of RUTH and previous trials13,20 show 
that raloxifene does not reduce the risk of estro-
gen-receptor–negative invasive breast cancer. The 
mechanism whereby raloxifene reduces the risk 
of estrogen-receptor–positive invasive breast can-
cer is not clear but is probably related to estrogen 
antagonism resulting in regression of subclini-
cal estrogen-receptor–positive cancers.
Raloxifene did not increase the overall risk of 
stroke but was associated with a 49 percent in-
crease in the incidence of fatal stroke. Raloxifene 
had no significant effect on the overall risk of 
death from cardiovascular causes or death from 
any cause. There was no effect of raloxifene on 
the risk of stroke in the MORE trial.10 Tamoxi-
fen increased the risk of stroke in most18,21-23 
but not all24 trials. In STAR,19 the incidence of 
stroke was similar in the raloxifene and tamoxi-
fen groups.
In the WHI trials, estrogen alone or with a 
progestin increased the risk of stroke by approxi-
mately 40 percent in healthy postmenopausal 
women.8,9 Among women with a recent history 
of stroke or transient ischemic attack, estrogen 
did not affect the risk of nonfatal stroke but in-
creased the risk of fatal stroke.25
Consistent with the findings of previous trials 
of estrogen and SERMs,7-9,18,26 we found that ral-
oxifene use was associated with an increased risk 
of venous thromboembolic events. There was a 
35 percent reduction in the risk of clinical verte-
bral fractures but no significant reduction in non-
vertebral fractures in the raloxifene group, con-
sistent with results in the MORE trial.27
Hot flushes, leg cramps, and peripheral ede-
ma, all known to be associated with raloxifene 
use,20,28 were reported more frequently by women 
assigned to raloxifene. Raloxifene did not increase 
the risk of all nonbreast cancers, including endo-
metrial cancer. The higher incidence of reported 
gallbladder disease was not observed in the study 
by Grady et al.26 but is a recognized complication 
of oral hormone therapy.29 Rates of cholecystec-
tomy were unrelated to the treatment assignment.
In conclusion, in postmenopausal women with 
CHD or at increased risk for CHD, treatment 
with raloxifene for a median of 5.6 years reduced 
the risk of invasive breast cancer and did not 
change the incidence of coronary events. In these 
women, the difference in the absolute rates of 
events that were decreased (i.e., breast cancer and 
clinical vertebral fractures) was similar to the 
difference in the absolute rates of events that were 
increased (i.e., venous thromboembolic events 
and fatal strokes). When considering the use of 
raloxifene in a postmenopausal woman, the clini-
cian should take into account the individual 
woman’s risk of disease and her personal prefer-
ences and weigh potential benefits against risks 
and against the availability of alternative inter-
ventions.
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